NEALS members attend the American Academy of Neurology Annual Meeting
The 69th American Academy of Neurology Annual Meeting took place in Boston, MA from April 22 – 28.
The Northeast ALS Consortium was well represented at the 2017 AAN. There was a NEALS membership satellite meeting on Wednesday, April 26th, where the co-chairs, Drs. Jonathan Glass and Terry Heiman-Patterson provided an update on NEALS initiatives and introduced the newest members. Dr. Angela Genge, McGill, closed the meeting with an update on Masitinib, on behalf of AB Science.
Dr. Gary Pattee from the Bryan LGH Medical Center led a day-long NEALS Bulbar Symposium in Charlestown, with over two dozen experts on speech and swallowing in attendance. The primary focus of the Symposium was to develop a workable bulbar document, based on current best clinical practices, to be incorporated into clinical use within the NEALS network.
Massachusetts General Hospital’s Alex Sherman, brought the NEALS Big Data Committee and NeuroBANK™ User Group together to advance the field of BIG Data in neurological diseases.
This year, an overwhelming number of NEALS members were invited to participate in the meeting; the membership gave multiple plenary talks, served as session chairs, participated in platform presentations, and presented abstract posters over the week-long program.
Some of the NEALS members who participated include:
Justin Kwan, MD, University of Maryland School of Medicine, ALS: Disease Mechanism and Therapeutics
Jonathan Katz, MD, California Pacific Medical Center; David Schoenfeld, PhD, Massachusetts General Hospital; and Jeremy Shefner, MD, PhD, Barrow Neurological Institute, The NEALS Randomized, Placebo Controlled Trial of Diaphragm Pacing in Patients with ALS
Robert Brown, MD, DPhil, University of Massachusetts, Postnatal CRISPR-mediated genome editing prolongs survival in a mouse model of amyotrophic lateral sclerosis
Dale Lange, MD, Hospital for Special Surgery; Mona Shahbazi, NP, Hospital for Special Surgery; Senda Ajroud-Driss, MD, Northwestern University; Stanley Appel, MD, Methodist Neurological Institute; and Vincenzo Silani, MD, University of Milan, Distinct patterns of disease progression in SOD1-associated familial ALS: A study of 25 mutations. Pooled analysis of two trials of pyrimethamine in familial ALS
Bryan Traynor, MD, PhD, National Instutute on Aging, The polymorphisms of CX3CR1 gene influence ALS survival in an Italian population-based study
Michael Weiss MD, FAAN, University of Washington Medical Center, Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis
Georgios Manousakis, MD, and David Walk, MD, Twin Cities ALS, Motor Neuron Diseases: Biomarkers, Outcome Measures, and Therapeutics
Richard Barohn, MD, University of Kansas Medical Center, "Best Of" Session: Neuromuscular Disease Therapeutics
Mark Bromberg, MD, PhD, FAAN, University of Utah, Clinical EMG II and III
Amanda Peltier, MD, Vanderbilt University Medical Center, Evaluation and Management of Autonomic Disorders I and II
Ezgi Tiryaki, MD, Twin Cities ALS, EMG Skills Workshop: Basic
Bjorn Oskarsson, MD, Mayo Clinic, Mexiletine for the treatment of muscle cramps in ALS: a randomized double-blind crossover trial
Dr. John Ravits, Professor of Clinical Neurosciences and Head of the ALS Translational Research Program at the University of California, San Diego (UCSD) received the Sheila Essey Award for ALS Research. Since 1996, The ALS Association and the American Academy of Neurology (AAN) have presented this prestigious award to honor and acknowledge an individual who is making significant contributions in research for ALS.